Aldebaran Therapeutics leverages human genetics and best-in-class antisense oligonucleotide (ASO) technology to deliver life-changing, precision ocular ASO medicines. Our focus on differentiated ASO technology, powered by Alloy Therapeutics' Genetic Medicines platform and novel AntiClastic™ ASO format, paves the way for a unique and rapid path to meaningful ocular solutions for patients.
Location: United States, Massachusetts, Waltham
Employees: 1-10